Saturday 17 October 2026
Export OPRX’s income statement to Excel — free account
OptimizeRx Corp.
OPRX Healthcare Health Information Services
OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024. In the quarter to June 2026, revenue fell 29.8%, EPS fell 150.0%, free cash flow grew 89.9% and total debt fell 33.1%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
8.50
0.35
−3.95%
Follow OPRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.83 | 17.44 | 45.41 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.09 | 1.10 | 2.08 | 3.48 | |
P/FCF ratio |
5.79 | 8.12 | 12.11 | 32.93 | |
P/Operating CF |
12.48 | (252.30) | 32.09 | 118.93 | |
P/B ratio |
0.82 | 0.91 | 1.77 | 3.11 | |
Price to Tangible BV |
5.00 | 6.20 | 13.68 | 42.52 | |
EV/Sales |
1.04 | 1.13 | 2.10 | 3.56 | |
EV/EBITDA |
6.27 | 6.12 | 13.41 | 82.57 | |
EV/Operating CF |
5.55 | 8.41 | 12.28 | 32.93 | |
EV/FCF |
5.51 | 8.34 | 12.24 | 33.68 | |
Quick Ratio |
5.27 | 5.07 | 2.91 | 2.90 | |
Current Ratio |
5.58 | 5.37 | 3.04 | 3.05 | |
Net Debt/EBITDA |
(4.06) | 1.75 | 0.23 | 2.60 | |
Debt/Assets |
11.57% | 13.96% | 14.51% | 16.50% | |
Debt/Equity |
0.15 | 0.18 | 0.20 | 0.23 | |
Asset Turnover |
0.59 | 0.64 | 0.63 | 0.65 | |
Operating CF/Net income |
(12.25) | 0.94 | 1.41 | 4.11 | |
Capex/Depreciation |
(0.03) | (0.01) | 0.15 | (0.01) | |
Interest Coverage |
(0.08) | 0.34 | 6.89 | 1.78 | |
Research and Development Expense of Revenue |
15.97% | 17.14% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
55.78% | 50.75% | 63.46% | 55.19% | |
Intangible Assets out of Total Assets |
0.67 | 0.66 | 0.63 | 0.67 | |
Share Based Compensation of Revenue |
10.77% | 9.21% | 6.08% | 7.50% | |
Graham Net Nets |
0.19 | 0.16 | 0.07 | 0.02 | |
Graham Number |
6.14 | 7.48 | 6.48 | 0.00 | |
Earnings Yield |
4.20% | 5.73% | 2.20% | 0.00% | |
Free Cash Flow Yield |
17.28% | 12.32% | 8.26% | 3.04% | |
Revenue per Share |
1.09 | 1.06 | 1.74 | 1.40 | |
Operating CF per Share |
0.46 | (0.02) | 0.38 | 0.17 | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
0.46 | (0.03) | 0.39 | 0.17 | |
Cash per Share |
1.28 | 1.08 | 1.26 | 1.05 | |
Shareholders Equity per Share |
6.98 | 6.91 | 6.91 | 6.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.98 | 6.91 | 6.91 | 6.58 | |
Free Cash Flow |
8.58 | (0.49) | 7.29 | 3.19 | |
Working Capital |
44.44 | 45.71 | 43.45 | 37.85 | |
Capital Expenditures |
(0.03) | (0.02) | 0.21 | (0.01) | |
Net Current Asset Value |
20.91 | 18.51 | 16.09 | 8.26 | |
EV/EBIT |
9.39 | 8.53 | 19.65 | 57.36 | |
Capex to Sales |
0.00 | 0.00 | (0.01) | 0.00 | |
Price to Operating Income |
9.86 | 8.30 | 19.45 | 56.09 | |
| Other line items | |||||
Average Receivables |
30.64 | 32.85 | 38.36 | 30.18 | |
Average Payables |
1.65 | 3.22 | 1.90 | 2.40 | |
Average Assets |
166.79 | 167.52 | 174.04 | 167.76 | |
Average Common Equity |
125.18 | 122.94 | 122.65 | 118.36 |
Columns are period end dates